092040 — Amicogen Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Amicogen, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	115,181	115,856	124,881	144,296	159,904
Cost of Revenue
Gross Profit	48,496	44,935	44,947	46,039	55,126
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	115,386	115,655	132,629	153,099	160,908
Operating Profit	-205	201	-7,748	-8,804	-1,003
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-880	40,814	9,663	-50,571	-23,230
Provision for Income Taxes
Net Income After Taxes	-237	32,291	4,741	-45,791	-20,690
Minority Interest
Net Income Before Extraordinary Items
Net Income	86.7	31,604	3,733	-47,220	-23,289
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	86.7	31,604	3,733	-47,220	-23,289
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-28.9	822	134	-1,047	-531
Dividends per Share